文献速递白血病造血干细胞移植与细胞治疗

无关供者α/β T细胞及B细胞清除造血干细胞移植治疗儿童急性白血病

Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

在2个大型儿童移植中心纳入60例缺乏配型相合同胞供者的儿童及年轻成人血液系统恶性肿瘤患者,接受无关供者TCRαβ/CD19清除外周血造血干细胞移植,4年总生存率69%,无白血病生存率64%,III-IV级急性GVHD发生率13%。

要点

  • 无关供者TCRαβ/CD19清除移植后4年总生存率69%(95%CI 52%-81%),无白血病生存率64%(95%CI 48%-76%)。
  • III-IV级急性GVHD 8例(13%),慢性GVHD 14例(26%),其中广泛型6例(11%)。
  • 非允许性DP错配与急性GVHD发生风险升高相关(OR 16.50,95%CI 1.67-163.42,P=.0166)。

核心结论

  • 无关供者TCRαβ/CD19清除外周血造血干细胞移植是治疗儿童及年轻成人白血病安全有效的方法。

研究设计与样本

  • 2014年10月至2019年9月在2个大型儿童移植中心纳入60例缺乏配型相合同胞供者的儿童及年轻成人血液系统恶性肿瘤患者。
  • 所有患者接受清髓性全身照射或白消安为基础的预处理,移植后未给予免疫抑制。
  • 所有急性白血病患者均进行微小残留病检测,77%的患者有DP分型资料。

主要发现

  • 植入成功率为98%。
  • 4年总生存率为69%(95%CI 52%-81%),无白血病生存率为64%(95%CI 48%-76%),淋系与髓系恶性肿瘤之间无差异(P=.6297和P=.5441)。
  • 1例(1.7%)发生原发性植入失败。
  • 11例复发(3年累积发生率21%,95%CI 11-34),8例发生非复发死亡(累积发生率15%,95%CI 6.7-26)。
  • III-IV级急性GVHD见于8例(13%),14例(26%)发生慢性GVHD,其中6例(11%)为广泛型。

临床怎么用

  • 原文结论认为无关供者TCRαβ/CD19清除外周血造血干细胞移植是治疗儿童及年轻成人白血病安全有效的方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Unrelated donor (URD) hematopoietic stem cell transplant (HSCT) is associated with an increased risk of severe graft-versus-host disease (GVHD). TCRαβ/CD19 depletion may reduce this risk, whereas maintaining graft-versus-leukemia. Outcome data with TCRαβ/CD19 depletion generally describe haploidentical donors, with relatively few URDs. We hypothesized that TCRαβ/CD19-depletion would attenuate the risks of GVHD and relapse for URD HSCT. Sixty pediatric and young adult (YA) patients with hematologic malignancies who lacked a matched-related donor were enrolled at 2 large pediatric transplantation centers between October 2014 and September 2019. All patients with acute leukemia had minimal residual disease testing, and DP typing was available for 77%. All patients received myeloablative total body irradiation- or busulfan-based conditioning with no posttransplant immune suppression. Engraftment occurred in 98%. Four-year overall survival was 69% (95% confidence interval [CI], 52%-81%), and leukemia-free survival was 64% (95% CI, 48%-76%), with no difference between lymphoid and myeloid malignancies (P = .6297 and P = .5441, respectively). One patient (1.7%) experienced primary graft failure. Relapse occurred in 11 patients (3-year cumulative incidence, 21%; 95% CI, 11-34), and 8 patients (cumulative incidence, 15%; 95% CI, 6.7-26) experienced nonrelapse mortality. Grade III to IV acute GVHD was seen in 8 patients (13%), and 14 patients (26%) developed chronic GVHD, of which 6 (11%) had extensive disease. Nonpermissive DP mismatch was associated with higher likelihood of acute GVHD (odds ratio, 16.50; 95% CI, 1.67-163.42; P = .0166) but not with the development of chronic GVHD. URD TCRαβ/CD19-depleted peripheral HSCT is a safe and effective approach to transplantation for children/YAs with leukemia. This trial was registered at www.clinicaltrials.gov as #NCT02323867.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Leahy AB, Li Y, Talano JA, et al. Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Adv. 2022. PMID: 34872106. doi:10.1182/bloodadvances.2021005492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。